PMID: 9175613Mar 1, 1997Paper

Sequence-independent effects of phosphorothiolated oligonucleotides on synaptic transmission and excitability in the hippocampus in vivo

Neuropharmacology
W C AbrahamW P Tate

Abstract

Antisense oligodeoxynucleotides (ODNs) have the potential to be a powerful tool for regulating gene expression and mRNA translation in spatially and temporally restricted domains. Prior to investigating the effects of antisense ODNs on hippocampal long-term potentiation, we investigated whether there are any non-specific effects of ODNs on perforant path synaptic transmission in the dentate gyrus of both pentobarbital-anaesthetized and awake, freely moving rats. Single injections of phosphorothioated antisense ODNs (4 nmol) to the immediate early gene zif/268 caused a rapid (within minutes) and long-lasting (>24 hr) profound depression of the perforant path evoked field potentials. This depressive effect was due to the phosphorothioate modification since a depression was not seen with unmodified antisense ODNs, relative to saline controls. Furthermore, the effect was not sequence-specific since modified sense ODNs caused the same degree of depression. The depression caused by the modified antisense ODNs was dose-dependent and specific to synaptic transmission, since antidromic population spikes elicited by mossy fibre stimulation were relatively unaffected compared to the orthodromic responses. A second unexpected side-effect o...Continue Reading

References

Jan 25, 1991·European Journal of Pharmacology·A Baskys, R C Malenka
Jan 1, 1991·Molecular Neurobiology·W C AbrahamW P Tate
Jan 1, 1989·Progress in Neurobiology·H Matthies
Mar 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·K RyderD Nathans
Feb 7, 1983·Brain Research·R J RacineS Hafner
Feb 16, 1995·Nature·T Pawson
Oct 1, 1994·Cellular and Molecular Neurobiology·B J ChiassonH A Robertson
Oct 1, 1994·Cellular and Molecular Neurobiology·W Brysch, K H Schlingensiepen
Jan 1, 1995·Brain Research. Molecular Brain Research·J WilliamsW Tate
Jun 21, 1994·Proceedings of the National Academy of Sciences of the United States of America·J R PerezR Narayanan
Sep 1, 1995·British Journal of Pharmacology·C H DaviesG L Collingridge
Sep 16, 1998·Current Opinion in Chemical Biology·S Agrawal, Q Zhao
May 1, 1992·Trends in Cell Biology·S Akhtar, R L Juliano

❮ Previous
Next ❯

Citations

Oct 9, 2001·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·N KipshidzeJ Moses
Oct 16, 2003·Current Opinion in Pharmacology·Michael Williams
Feb 14, 2002·Kidney International·Justin L RickerVincent H Gattone
Apr 7, 1999·Antisense & Nucleic Acid Drug Development·A W Szklarczyk, L Kaczmarek
Apr 26, 2006·Proceedings of the National Academy of Sciences of the United States of America·Yasunobu YasoshimaTakashi Yamamoto
May 18, 2004·Neuroscience·T Holen, C V Mobbs
Nov 10, 2000·Methods : a Companion to Methods in Enzymology·K Scarbrough
Jun 1, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·A M BabcockD J Poulsen
Nov 14, 2019·Scientific Reports·Maria Carolina GonzalezMartín Cammarota

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.